Mergers & Acquisitions
ZLB Behring purchases CytoGam immunoglobulin therapy from MedImmune for $120 million cash
Published in Blood Weekly, January 18th, 2007
CytoGam is an intravenous immunoglobulin enriched in antibodies against cytomegalovirus (CMV), which is indicated for preventing CMV disease associated with transplantation of the kidney, lung, liver, pancreas and heart. CMV is the most common cause of life-threatening infection occurring in solid organ transplants.
ZLB Behring paid U.S. $120 million in cash, $70 million of which is subject to achievement of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-01-18)
More Articles from Blood Weekly
- Blood Safety
Northfield Laboratories reports preliminary top-line data in pivotal Phase III trauma study - Blood Substitutes
Research from University of Erlangen, Department of General Surgery in the area of blood substitutes published - Cardiology
New cardiology research from Washington Hospital Center outlined - Rectal Cancer Risk Factors
Research data from Hospital, Department of Surgery update understanding of rectal cancer risk factors - Sepsis
Reports summarize sepsis research from National Defense Medical Center, Department of Surgery - Sepsis
Research from Children's Hospital in the area of sepsis in children published - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
